Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Ameriprise Financial, Inc.

AMP
Financials · Asset Management

Ameriprise Financial, Inc. compounds quietly. Returns above 15% and growth without drama — priced like it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is topping out (6 weeks in) while the P/BV sits at the 39th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +58.6% year on year, with the the net margin at 19.1%. What settles it: the next one or two quarters of delivery.

Stage
Consistent
fundamental trajectory, 12 quarters
Price
$554
+10.4% 1Y
P/BV
7.7×
39th pctile
of its own 5-year range
Revenue (Mar 26)
$4.8 B
+10.6% YoY
Profit (Mar 26)
$0.9 B
+58.6% YoY
Net margin
19.1%
+5.8 pp YoY
ROE
63%
FY25
ROA
2.27%
latest
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Ameriprise Financial, Inc. trades at $554, losing momentum at the top and 6 weeks into that stage. That is +16.1% against its own 200-day average. It sits at 100% of a 52-week range of $434 to $554. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is losing momentum at the top — week 6 of stage 3. At $554 it trades +16.1% versus its 200-day average and sits at 100% of its 52-week range ($434–$554).

Aug 26: $554 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+16.1% versus the 200-day line, week 6 of stage 3
Price50-day avg200-day avg
S2S2S1S4$595$519$442$366$289$$554$477Jul 23Apr 24Jan 25Oct 25Aug 26
S2S2S1S4$595$519$442$366$289$$554$477Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +509% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.

Ameriprise Financial, Inc. trades at 7.7× P/BV, mid-range by its own standards (39th percentile). Its long-run median P/BV is 8.4×, measured across 5.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/BV of 7.7× is mid-range by its own standards (39th percentile), against a long-run median of 8.4× measured over 5.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/BV 7.7× vs a 8.4× long-run median P/BV, weekly (left axis); book value per share, quarterly steps drawn weekly (right axis). 5.1-year window; brief peaks above 11× shown pinned at the top. The book value / share bars are red where the reading is lower than the quarter before.
mid-range by its own standards (39th percentile)
P/BVMedianBook value / share (quarterly)
11.4×$74.09.7×$55.58.1×$37.06.4×$18.54.8×$0.0×$8.08×$69Jul 21Oct 22Jan 24Apr 25Aug 26
11.4×$74.09.7×$55.58.1×$37.06.4×$18.54.8×$0.0×$8.08×$69Jul 21Jan 24Aug 26
PEG 0.93 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
2.1×1.7×1.3×0.9×0.4××0.93×Sep 21Sep 22Dec 23Mar 25Jun 26
2.1×1.7×1.3×0.9×0.4××0.93×Sep 21Dec 23Jun 26
P/BV
7.7×
39th percentile of 5y
PEG
0.70
as reported

Why the multiple sits where it does: over the past year book value grew while the price moved +10.4% — price and book moved together, holding the multiple in its range.

The price move, decomposed: over 5y, of the +15.8%/yr price move, ~+7.9%/yr came from book-value growth and ~+7.9 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the book-value line underneath it, not the multiple.

03 · Stage: Consistent

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Ameriprise Financial, Inc. reads as consistent on its fundamental arc. Consistent — revenue and EPS growth have stayed positive through the window, with ROE at 62.8% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +7.1% in FY25, profit +4.7% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
11%44%10%27%8.8%10%7.5%−6.5%6.2%−23%%%7.1%4.7%FY21FY23FY25
11%44%10%27%8.8%10%7.5%−6.5%6.2%−23%%%7.1%4.7%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit accelerating
RevenueProfitEPS
12%45%10%28%8.7%11%7.3%−6.2%5.8%−23%%%8.4%30.4%36.6%Jun 23Sep 24Mar 26
12%45%10%28%8.7%11%7.3%−6.2%5.8%−23%%%8.4%30.4%36.6%Jun 23Sep 24Mar 26
ROE Trailing-twelve-month net profit as a share of quarter-end equity, %.
the return curve, computed quarterly
ROE
76%68%61%53%45%%62.8%Jun 23Dec 23Sep 24Jun 25Mar 26
76%68%61%53%45%%62.8%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest +8.4% · span +6.2% to +11.2%
Profit growth
Rising
latest +30.4% · span −18.5% to +33.6%
EPS growth
Rising
latest +36.6% · span −14.4% to +40.0%
ROE
Rising
latest 62.8% · span 47.5%–74.0%

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+7.1%+9.0%
Profit+4.7%+4.2%
EPS+9.8%+9.4%
Stock price+10.4%+17.1%+15.8%+19.1%
Revenue YoY (Mar 26)
+10.6%
latest quarter vs a year ago
Profit YoY (Mar 26)
+58.6%
latest quarter vs a year ago
Revenue 10y
8.4%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

54.8/100 — rank 27 of 29 in Asset Management · 46% evidence confidence · provisional, ranked below fully-evidenced peers

Ameriprise Financial, Inc. scores 54.8 out of 100 against the 29 companies it is compared with in Asset Management, ranking 27. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 16.6 + 16.4 + 7.1 + 14.7 = 54.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.

Ameriprise Financial, Inc. reported $4.8 B of income in the Mar 26 quarter, +10.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 8.4% a year. The last full year, FY25, came in at $18.5 B. The last four reported quarters add to $18.9 B.

FY25 revenue came in at $18.5 B (+7.1% on the year), capping 4 years at 8.4% compound. The latest quarter (Mar 26) printed $4.8 B, +10.6% year on year — the 12th consecutive quarter of year-over-year growth.

FY25 revenue $18.5 B (+7.1% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
8.4% a year over 4 years
RevenueYoY growth
2011%1510%10.08.8%5.07.5%0.06.2%$ B%$19B7.1%FY21FY23FY25
2011%1510%10.08.8%5.07.5%0.06.2%$ B%$19B7.1%FY21FY23FY25
Mar 26: $4.8 B (+10.6% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
5.414%4.011%2.78.3%1.35.7%0.03.1%$ B%$5B10.6%Jun 23Sep 24Mar 26
5.414%4.011%2.78.3%1.35.7%0.03.1%$ B%$5B10.6%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +8.4% growth against the decade's 8.4% — the current year is running in line with its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +8.4% over the last 4 quarters against +9.0%/yr over the last 8 — stabilising; TTM profit +30.4% vs +11.6%/yr — accelerating.

06 · Net margin

Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.

Ameriprise Financial, Inc.'s net margin is 19.1% in the Mar 26 quarter, +5.8 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 16.5% to 25.6%. The current quarter sits inside that band.

The latest quarter's net margin is 19.1%, +5.8 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 16.5%–25.6%.

Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

FY25: 19.3% Net margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 16.5–25.6% band over 5 years
net marginYoY change (pp)
26%3.9%24%1.4%21%−1.2%18%−3.8%16%−6.3%%%19.3%−0.4%FY21FY23FY25
26%3.9%24%1.4%21%−1.2%18%−3.8%16%−6.3%%%19.3%−0.4%FY21FY23FY25
Mar 26: 19.1% net margin (+5.8 pp YoY) Quarterly net margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Net profit as a share of total revenue, per quarter.
Net marginYoY change (pp)
25%16%21%9.1%17%1.9%13%−5.4%8.3%−13%%%19.1%5.8%Jun 23Sep 24Mar 26
25%16%21%9.1%17%1.9%13%−5.4%8.3%−13%%%19.1%5.8%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Ameriprise Financial, Inc. earned $0.9 B of net profit in the Mar 26 quarter, +58.6% year on year. Full-year FY25 profit was $3.6 B. The 4-year compound rate is 1.0%. That is 19.1% of the quarter's revenue. The same quarter a year earlier earned $0.6 B.

Mar 26 profit was $0.9 B, +58.6% year on year. On the full year, FY25 printed $3.6 B (+4.7%), and the 4-year compound rate is 1.0%.

FY25 profit $3.6 B (+4.7% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
1.0% a year over 4 years
Net profitYoY growth
3.837%2.922%1.97.0%1.0−7.9%0.0−23%$ B%$4B4.7%FY21FY23FY25
3.837%2.922%1.97.0%1.0−7.9%0.0−23%$ B%$4B4.7%FY21FY23FY25
Mar 26: $0.9 B (+58.6% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
1.2199%0.9135%0.670%0.35.4%0.0−59%$ B%$1B58.6%Jun 23Sep 24Mar 26
1.2199%0.9135%0.670%0.35.4%0.0−59%$ B%$1B58.6%Jun 23Sep 24Mar 26

Why profit moved: revenue contributed +10.6% and the margin +5.8 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +39.8% vs revenue +8.4%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Asset quality — the ladder

Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.

Loan-book quality history is not available for Ameriprise Financial, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.

We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.

Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.

09 · The loan book

The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.

Ameriprise Financial, Inc.'s revenue grew +7.1% in FY25 to $18.5 B, so the book is growing. The latest quarter ran +10.6% year on year. The net margin on that income is 19.1%, +5.8 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.

FY25 revenue was $18.5 B, +7.1% on the year, and the latest quarter ran +10.6% year on year. The net margin on that revenue is 19.1% this quarter (+5.8 pp YoY) — growth with a widening margin on it.

FY25: revenue $18.5 B (+7.1% YoY) with the net margin at 19.3% Revenue by fiscal year, $ B (bars, left); net margin, % (line, right). 5-year window. A bar is red when it is lower than the year before.
RevenueNet margin
2026%1524%10.021%5.018%0.016%$ B%$19B19.3%FY21FY22FY23FY24FY25
2026%1524%10.021%5.018%0.016%$ B%$19B19.3%FY21FY23FY25

The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.

10 · Returns on equity and assets

Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.

Ameriprise Financial, Inc. earns a return on equity of 54% in FY25. Its trough over the ladder below was 54% in FY23. On the asset side every $100 of the balance sheet earned about $2.27, which is the return before leverage is applied.

FY25 ROE came in at 54%, recovered from a FY23 trough of 54%. On assets, the latest reading is about 2.27% — every $100 the bank deploys earns roughly $2.27 a year. That clears the bar a bank must beat for its book value to compound.

FY25: ROE 54% Return on equity by fiscal year, % (line, left). 5-year window. Latest return on assets: 2.27%. A lender is judged on ROE and ROA — return on invested capital does not apply to a bank.
up from a FY23 trough of 54%
ROE
85%77%69%60%52%%54.4%FY21FY23FY25
85%77%69%60%52%%54.4%FY21FY23FY25
Jun 26: ROE 65.7% (TTM) Trailing-twelve-month return on equity (left), per quarter, %. Last 12 quarters, anchored to the annual figure.
ROE (TTM)
78%73%68%63%58%%65.7%Sep 23Dec 24Jun 26
78%73%68%63%58%%65.7%Sep 23Dec 24Jun 26

Why ROE moved: profit compounded 1.0% a year over 4 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.

11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Ameriprise Financial, Inc. paid $6.40 per share over the last four reported quarters, up 8.1% on a year ago. The most recent declaration was $1.60 for Mar 26. Against the current price of $554 that is a trailing yield of 1.16%, measured on dividends already paid rather than on a forecast.

Ameriprise Financial, Inc. paid $6.40 per share across the last four reported quarters, most recently $1.60 for Mar 26. That is up 8.1% against the same quarter a year earlier. Against the current price of $554 the trailing twelve months work out to 1.16% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $1.60 (Mar 26)
Dividend per share
1.71.30.90.40.0$ B$2BJun 23Dec 23Sep 24Jun 25Mar 26
1.71.30.90.40.0$ B$2BJun 23Sep 24Mar 26
12 · Debt

Debt

For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.

A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

3.7% of Ameriprise Financial, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 3.7% of the float is sold short, and at typical trading volumes it would take about 4.1 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
3.7%
of the tradable float
Days to cover
4.1
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Ameriprise Financial, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.

The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.

15 · Related companies · Asset Management
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Victory Capital Holdings, Inc.VCTR 66.2/100Favorable setup76% evidence LEADER 24.7/35 Income 64.1% · PAT 29.1% 71% evidence 16.5/25 ROA 3.6% · ROE 6.4% · GNPA — 68% evidence 7.9/20 P/BV 2.29× · P/BV÷ROE 0.36 70% evidence 17.1/20 RS sector 21% · RS bench 25.6% · 1Y 45.6%12 of 12 weeks ahead 100% evidence
Exact sum: 24.7 + 16.5 + 7.9 + 17.1 = 66.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Raymond James Financial, Inc.RJF 59.0/100Mixed-positive evidence60% evidence BREAKING OUT 21.3/35 Income — · PAT — 26% evidence 15.3/25 ROA 1.4% · ROE 9.7% · GNPA — 68% evidence 11.0/20 P/BV 2.24× · P/BV÷ROE 0.23 70% evidence 11.4/20 RS sector -3.3% · RS bench 0% · 1Y 8.3%4 of 12 weeks ahead 100% evidence
Exact sum: 21.3 + 15.3 + 11 + 11.4 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Affiliated Managers Group, Inc.AMG 57.8/100Mixed-positive evidence60% evidence BREAKING OUT 20.1/35 Income — · PAT — 26% evidence 14.6/25 ROA 1.6% · ROE 6.1% · GNPA — 68% evidence 6.9/20 P/BV 2.94× · P/BV÷ROE 0.48 70% evidence 16.2/20 RS sector 14.9% · RS bench 19.4% · 1Y 81.5%10 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 14.6 + 6.9 + 16.2 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4SEI Investments CompanySEIC 56.7/100Mixed-positive evidence60% evidence BREAKING OUT 17.9/35 Income — · PAT — 26% evidence 17.6/25 ROA 5.2% · ROE 7.7% · GNPA — 68% evidence 5.9/20 P/BV 4.21× · P/BV÷ROE 0.55 70% evidence 15.3/20 RS sector 5.7% · RS bench 9.5% · 1Y 19.7%6 of 12 weeks ahead 100% evidence
Exact sum: 17.9 + 17.6 + 5.9 + 15.3 = 56.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
5BlackRock, Inc.BLK 53.3/100Mixed-positive evidence80% evidence BASING 22.9/35 Income 26.5% · PAT 9.2% 81% evidence 16.4/25 ROA 2.5% · ROE 7.9% · GNPA — 68% evidence 8.4/20 P/BV 2.64× · P/BV÷ROE 0.33 70% evidence 5.6/20 RS sector -8.3% · RS bench -5.1% · 1Y 0.5%0 of 12 weeks ahead 100% evidence
Exact sum: 22.9 + 16.4 + 8.4 + 5.6 = 53.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.3% and the one-year return is 0.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
6Blackstone Inc.BX 50.6/100Mixed-positive evidence60% evidence TURNING 20.8/35 Income — · PAT — 26% evidence 18.1/25 ROA 5% · ROE 10.8% · GNPA — 68% evidence 4.4/20 P/BV 9.7× · P/BV÷ROE 0.9 70% evidence 7.3/20 RS sector -14.2% · RS bench -11.8% · 1Y -18.8%1 of 12 weeks ahead 100% evidence
Exact sum: 20.8 + 18.1 + 4.4 + 7.3 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
7State Street CorporationSTT 50.3/100Mixed-positive evidence60% evidence LEADER 17.7/35 Income — · PAT — 26% evidence 9.3/25 ROA 0.3% · ROE 3.9% · GNPA — 68% evidence 7.1/20 P/BV 1.66× · P/BV÷ROE 0.43 70% evidence 16.2/20 RS sector 18.2% · RS bench 23% · 1Y 66.8%12 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 9.3 + 7.1 + 16.2 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Janus Henderson Group plcJHG 50.0/100Mixed-positive evidence70% evidence 19.9/35 Income 24.5% · PAT 100% 71% evidence 11.1/25 ROA 1.2% · ROE 1.9% · GNPA — 68% evidence 5.5/20 P/BV 1.53× · P/BV÷ROE 0.81 70% evidence 13.5/20 RS sector 6.2% · RS bench 0.6% · 1Y 28.9%0 of 7 weeks ahead to 2026-07-02 70% evidence
Exact sum: 19.9 + 11.1 + 5.5 + 13.5 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Invesco Ltd.IVZ 49.8/100Mixed-negative evidence60% evidence BREAKING OUT 19.1/35 Income — · PAT — 26% evidence 10.4/25 ROA 1% · ROE 2.4% · GNPA — 68% evidence 7.3/20 P/BV 0.94× · P/BV÷ROE 0.39 70% evidence 13.0/20 RS sector 8.4% · RS bench 12.4% · 1Y 54.4%8 of 12 weeks ahead 100% evidence
Exact sum: 19.1 + 10.4 + 7.3 + 13 = 49.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10T. Rowe Price Group, Inc.TROW 49.7/100Mixed-negative evidence60% evidence BREAKING OUT 17.3/35 Income — · PAT — 26% evidence 15.7/25 ROA 2.8% · ROE 6.1% · GNPA — 68% evidence 7.5/20 P/BV 2.21× · P/BV÷ROE 0.36 70% evidence 9.2/20 RS sector -2.8% · RS bench 0.6% · 1Y 10.2%9 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 15.7 + 7.5 + 9.2 = 49.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Ares Management CorporationARES 48.7/100Mixed-negative evidence60% evidence BREAKING OUT 20.7/35 Income — · PAT — 26% evidence 14.1/25 ROA 1.5% · ROE 7.1% · GNPA — 68% evidence 4.8/20 P/BV 6.11× · P/BV÷ROE 0.86 70% evidence 9.1/20 RS sector -11.7% · RS bench -9.3% · 1Y -24.2%5 of 12 weeks ahead 100% evidence
Exact sum: 20.7 + 14.1 + 4.8 + 9.1 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12StepStone Group Inc.STEP 46.6/100Thin evidence · provisional55% evidence BASING 23.2/35 Income 69.7% · PAT — 45% evidence 13.4/25 ROA 6.9% · ROE 0.5% · GNPA — 68% evidence 9.8/20 P/BV -9.31× · P/BV÷ROE — 10% evidence 0.2/20 RS sector -24.7% · RS bench -22.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence
Exact sum: 23.2 + 13.4 + 9.8 + 0.2 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Franklin Resources, Inc.BEN 46.5/100Mixed-negative evidence60% evidence LEADER 17.5/35 Income — · PAT — 26% evidence 8.8/25 ROA 0.4% · ROE 1.8% · GNPA — 68% evidence 5.8/20 P/BV 1.44× · P/BV÷ROE 0.8 70% evidence 14.4/20 RS sector 16% · RS bench 20.5% · 1Y 43.1%11 of 12 weeks ahead 100% evidence
Exact sum: 17.5 + 8.8 + 5.8 + 14.4 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Hamilton Lane IncorporatedHLNE 45.5/100Mixed-negative evidence76% evidence TURNING 15.1/35 Income 6.6% · PAT 24% 71% evidence 17.8/25 ROA 3.6% · ROE 9.6% · GNPA — 68% evidence 6.3/20 P/BV 4.75× · P/BV÷ROE 0.49 70% evidence 6.3/20 RS sector -22.9% · RS bench -21% · 1Y -34.3%1 of 12 weeks ahead 100% evidence
Exact sum: 15.1 + 17.8 + 6.3 + 6.3 = 45.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
15Corebridge Financial, Inc.CRBG 44.7/100Thin evidence · provisional55% evidence BREAKING OUT 19.1/35 Income 14.6% · PAT -71.3% 45% evidence 5.2/25 ROA 0% · ROE -0.5% · GNPA — 68% evidence 9.8/20 P/BV 1.01× · P/BV÷ROE — 10% evidence 10.6/20 RS sector -7.3% · RS bench -4.4% · 1Y -5.1%9 of 12 weeks ahead 100% evidence
Exact sum: 19.1 + 5.2 + 9.8 + 10.6 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Principal Financial Group, Inc.PFG 43.3/100Mixed-negative evidence60% evidence BREAKING OUT 15.9/35 Income — · PAT — 26% evidence 7.5/25 ROA 0.1% · ROE 3.6% · GNPA — 68% evidence 6.4/20 P/BV 1.91× · P/BV÷ROE 0.53 70% evidence 13.5/20 RS sector 7.3% · RS bench 11.5% · 1Y 50.4%9 of 12 weeks ahead 100% evidence
Exact sum: 15.9 + 7.5 + 6.4 + 13.5 = 43.3 · Decision use: Price leads the evidence: RS versus the benchmark is 11.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
17Blue Owl Capital Inc.OWL 42.6/100Mixed-negative evidence60% evidence TURNING 19.5/35 Income — · PAT — 26% evidence 12.1/25 ROA 1.6% · ROE 1.9% · GNPA — 68% evidence 4.5/20 P/BV 2.94× · P/BV÷ROE 1.55 70% evidence 6.5/20 RS sector -22.2% · RS bench -20.4% · 1Y -41.4%0 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 12.1 + 4.5 + 6.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Brookfield Asset Management Ltd.BAM 41.6/100Mixed-negative evidence76% evidence BASING 16.2/35 Income 21.5% · PAT 10.5% 71% evidence 15.5/25 ROA 3.3% · ROE 5.3% · GNPA — 68% evidence 3.4/20 P/BV 9.38× · P/BV÷ROE 1.77 70% evidence 6.5/20 RS sector -11.6% · RS bench -8.8% · 1Y -15.2%0 of 12 weeks ahead 100% evidence
Exact sum: 16.2 + 15.5 + 3.4 + 6.5 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Equitable Holdings, Inc.EQH 37.7/100Mixed-negative evidence76% evidence BREAKING OUT 12.0/35 Income -23.4% · PAT -126% 71% evidence 12.7/25 ROA 0.3% · ROE 24.1% · GNPA — 68% evidence 3.4/20 P/BV 38.27× · P/BV÷ROE 1.59 70% evidence 9.6/20 RS sector -8.4% · RS bench -5.6% · 1Y -7.2%9 of 12 weeks ahead 100% evidence
Exact sum: 12 + 12.7 + 3.4 + 9.6 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20TPG Inc.TPG 36.5/100Mixed-negative evidence64% evidence TURNING 16.6/35 Income 11.5% · PAT 100% 71% evidence 4.4/25 ROA -0.8% · ROE -3.4% · GNPA — 68% evidence 9.4/20 P/BV 5.73× · P/BV÷ROE — 10% evidence 6.1/20 RS sector -17.4% · RS bench -15.2% · 1Y -20.6%1 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 4.4 + 9.4 + 6.1 = 36.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21KKR & Co. Inc.KKR 35.7/100Mixed-negative evidence60% evidence TURNING 16.8/35 Income — · PAT — 26% evidence 7.9/25 ROA 0.2% · ROE 2.1% · GNPA — 68% evidence 4.9/20 P/BV 2.7× · P/BV÷ROE 1.28 70% evidence 6.1/20 RS sector -16.2% · RS bench -13.9% · 1Y -24.2%0 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 7.9 + 4.9 + 6.1 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Brookfield CorporationBN 35.4/100Mixed-negative evidence76% evidence ASLEEP 20.1/35 Income -6.7% · PAT 100% 71% evidence 8.6/25 ROA 0.7% · ROE 0.5% · GNPA — 68% evidence 3.7/20 P/BV 2.95× · P/BV÷ROE 5.9 70% evidence 3.0/20 RS sector -13.3% · RS bench -10.3% · 1Y 3.4%1 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 8.6 + 3.7 + 3 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Apollo Global Management, Inc.APO 31.8/100Adverse evidence64% evidence ASLEEP 12.3/35 Income 28.2% · PAT -45% 71% evidence 5.2/25 ROA -0.5% · ROE -3.9% · GNPA — 68% evidence 9.7/20 P/BV 3.22× · P/BV÷ROE — 10% evidence 4.6/20 RS sector -9.9% · RS bench -7% · 1Y -6.2%4 of 12 weeks ahead 100% evidence
Exact sum: 12.3 + 5.2 + 9.7 + 4.6 = 31.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Blue Owl Capital CorporationOBDC 27.0/100Adverse evidence62% evidence BASING 9.4/35 Income -11% · PAT -50.5% 55% evidence 10.1/25 ROA — · ROE 0.5% · GNPA — 34% evidence 4.7/20 P/BV 0.77× · P/BV÷ROE 1.53 70% evidence 2.8/20 RS sector -19.5% · RS bench -16.9% · 1Y -21%0 of 12 weeks ahead 100% evidence
Exact sum: 9.4 + 10.1 + 4.7 + 2.8 = 27 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25The Carlyle Group Inc.CG 25.3/100Adverse evidence64% evidence BASING 7.1/35 Income -28.9% · PAT -44% 71% evidence 6.5/25 ROA 0.3% · ROE -2.1% · GNPA — 68% evidence 9.6/20 P/BV 3.22× · P/BV÷ROE — 10% evidence 2.1/20 RS sector -18.2% · RS bench -15.9% · 1Y -18.6%0 of 12 weeks ahead 100% evidence
Exact sum: 7.1 + 6.5 + 9.6 + 2.1 = 25.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Pershing Square Inc.PS 56.4/100Thin evidence · provisional42% evidence ASLEEP 28.6/35 Income 68.8% · PAT 100% 71% evidence 7.8/25 ROA 1% · ROE -35.8% · GNPA — 68% evidence 10.0/20 P/BV — · P/BV÷ROE — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 2 weeks ahead 0% evidence
Exact sum: 28.6 + 7.8 + 10 + 10 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Ameriprise Financial, Inc.this pageAMP 54.8/100Thin evidence · provisional46% evidence BREAKING OUT 16.6/35 Income — · PAT — 10% evidence 16.4/25 ROA — · ROE 17.9% · GNPA — 34% evidence 7.1/20 P/BV 6.48× · P/BV÷ROE 0.36 70% evidence 14.7/20 RS sector -0.2% · RS bench 3.2% · 1Y 9.6%4 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 16.4 + 7.1 + 14.7 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Northern Trust CorporationNTRS 51.9/100Thin evidence · provisional46% evidence LEADER 18.4/35 Income — · PAT — 10% evidence 12.5/25 ROA — · ROE 6% · GNPA — 34% evidence 8.6/20 P/BV 1.99× · P/BV÷ROE 0.33 70% evidence 12.4/20 RS sector 7% · RS bench 11.2% · 1Y 45.2%12 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 12.5 + 8.6 + 12.4 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Ares Capital CorporationARCC 38.0/100Thin evidence · provisional46% evidence BASING 16.5/35 Income — · PAT — 10% evidence 10.6/25 ROA — · ROE 1.2% · GNPA — 34% evidence 6.0/20 P/BV 0.96× · P/BV÷ROE 0.8 70% evidence 4.9/20 RS sector -13.5% · RS bench -10.6% · 1Y -12.9%0 of 12 weeks ahead 100% evidence
Exact sum: 16.5 + 10.6 + 6 + 4.9 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Ameriprise Financial, Inc.'s stock price today?

Ameriprise Financial, Inc. trades at $554, +10.4% over the past year. The company is valued at $49.0 B. The stock sits at 100% of its 52-week range of $434–$554, +16.1% versus its 200-day average. On the tape, the price is topping out, 6 weeks in. — as of 5 August 2026.

What were Ameriprise Financial, Inc.'s latest quarterly results?

Ameriprise Financial, Inc. reported total income of $4.8 B and net profit of $0.9 B for the Mar 26 quarter. Income rose 10.6% and profit rose 58.6% year on year. Earnings per share were $9.68. The net margin was 19.1%, 5.8 pp higher than a year earlier. — as of 5 August 2026.

What is Ameriprise Financial, Inc.'s revenue?

Ameriprise Financial, Inc. reported revenue of $4.8 B in the Mar 26 quarter, +10.6% year on year. For the full FY25 fiscal year, revenue was $18.5 B (+7.1%). Over the last 4 years revenue compounded at 8.4% a year. — as of 5 August 2026.

What is Ameriprise Financial, Inc.'s profit?

Ameriprise Financial, Inc. earned $0.9 B of net profit in the Mar 26 quarter, +58.6% year on year. Full-year FY25 profit was $3.6 B. The net margin ran 19.1% in the latest quarter. — as of 5 August 2026.

What is Ameriprise Financial, Inc.'s market cap?

Ameriprise Financial, Inc.'s market capitalisation is $49.0 B at a stock price of $554. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Ameriprise Financial, Inc.'s P/BV ratio?

Ameriprise Financial, Inc. trades at a P/BV of 7.7×, at the 39th percentile of its own 5-year range, against a long-run median of 8.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Ameriprise Financial, Inc. pay a dividend?

Yes — Ameriprise Financial, Inc. declared $1.60 per share for Mar 26, and $6.40 per share across the last four reported quarters. The latest quarter is up 8.1% on the same quarter a year earlier. — as of 5 August 2026.

What is Ameriprise Financial, Inc.'s dividend per share?

Ameriprise Financial, Inc.'s most recently declared dividend is $1.60 per share for Mar 26, giving $6.40 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.

What is Ameriprise Financial, Inc.'s dividend yield?

Ameriprise Financial, Inc.'s trailing dividend yield is 1.16%: $6.40 declared per share across the last four reported quarters, against a share price of $554. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.

Is Ameriprise Financial, Inc. overvalued?

On its own history, Ameriprise Financial, Inc. looks mid-range against its own history: its P/BV of 7.7× sits at the 39th percentile of its 5-year range (long-run median 8.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.

Is Ameriprise Financial, Inc. growing?

Yes — Ameriprise Financial, Inc. is growing: latest-quarter revenue +10.6% year on year, profit +58.6%, and the the net margin +5.8 pp at 19.1%. The 4-year compound rates are 8.4% (revenue) and 1.0% (profit). The earnings engine currently reads: improving — as of 5 August 2026.

How is Ameriprise Financial, Inc. performing?

Ameriprise Financial, Inc. is topping out, 6 weeks in. Its latest quarter's income rose 10.6% and profit rose 58.6% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Ameriprise Financial, Inc. in?

Consistent — revenue and EPS growth have stayed positive through the window, with ROE at 62.8% and holding. The read comes from the last 12 quarters of growth (revenue growth +8.4% latest, profit growth +30.4% latest, eps growth +36.6% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Ameriprise Financial, Inc. in an uptrend?

It is stalling — the price is topping out (week 6 of stage 3), trading +16.1% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Ameriprise Financial, Inc. beating the market?

On recent form, yes — Ameriprise Financial, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +509% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.

Will Ameriprise Financial, Inc.'s stock price go up?

This page publishes no price forecast for Ameriprise Financial, Inc. What it measures instead: the stock price is $554, the price is topping out 6 weeks in. Its P/BV of 7.7× sits at the 39th percentile of its own 5-year range. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Ameriprise Financial, Inc.?

Somewhat — short interest is 3.7% of Ameriprise Financial, Inc.'s tradable float, about 4.1 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Is Ameriprise Financial, Inc.'s loan book healthy?

We do not hold quarterly loan-book quality numbers for Ameriprise Financial, Inc., so this page says that plainly. The cleanest available reads are revenue growth (+7.1% in FY25) and the net margin on it (19.1%) — as of 5 August 2026.

Where is Ameriprise Financial, Inc. in its business cycle?

Ameriprise Financial, Inc.'s FY25 net margin was 19.3%, against a 5-year band of 16.5%–25.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 19.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Ameriprise Financial, Inc. story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Ameriprise Financial, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Ameriprise Financial, Inc. compounds quietly. Returns above 15% and growth without drama — priced like it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI